FindTrial
Sign In

0.9 % NaCl

DRUG8 trials

Sponsors

Fresenius Kabi, Kantonsspital Baselland Bruderholz, TC Erciyes University, Ever Neuro Pharma GmbH, Piotr Czempik

Conditions

Abdominal SurgeryAlopecia AndrogenicaAnemiaCadasilCardiac SurgeryCoronary Artery DiseaseDiabetes Mellitus Type 2Multiple Organ Failure

Phase 2

CERebrolysin In CADASIL
Active, not recruitingNCT05755997
Ever Neuro Pharma GmbHCadasil
Start: 2023-11-29End: 2026-12-31Target: 30Updated: 2025-02-25

Phase 3

Effects of Voluven on Hemodynamics and Tolerability of Enteral Nutrition in Patients With Severe Sepsis
CompletedNCT00464204
Fresenius KabiSepsis
Start: 2007-07-31End: 2010-12-31Updated: 2012-01-11
Effect of Vitamin D Supplementation on Blood Pressure and HbA1c Levels in Patients With T2D
CompletedNCT01585051
Kantonsspital Baselland BruderholzDiabetes Mellitus Type 2
Start: 2009-01-31End: 2010-06-30Updated: 2012-04-25
Dalargin for Prevention of Organ Disfunction in High-Risk Abdominal Surgery
Active, not recruitingNCT07404358
Botkin HospitalAbdominal Surgery, Multiple Organ Failure, Postoperative Complications
Start: 2025-05-13End: 2026-12-20Updated: 2026-02-11

Phase 4

Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy
CompletedNCT02137863
TC Erciyes UniversityRadiographic Contrast Agent Nephropathy
Start: 2011-06-30End: 2012-07-31Updated: 2014-05-14
Use of Epoetin Alfa and Iron Derisomaltose in Treatment of Anemia in Patients With Sepsis or Septic Shock: a Randomized Controlled Trial
RecruitingNCT06670963
Piotr CzempikAnemia, Sepsis, Septic Shock
Start: 2024-11-10End: 2027-04-01Target: 200Updated: 2024-12-27
Intrapleural Ropivacaine Infusion in Cardiac Surgery
RecruitingNCT07116343
Saint Petersburg State University, RussiaCardiac Surgery, Coronary Artery Disease, Valvular Diseases
Start: 2025-10-22End: 2027-12-01Target: 116Updated: 2026-03-10

Unknown Phase

Exosome Treatment and Hair Growth
CompletedNCT06930326
COSMEDICIAN AP SDN BHDAlopecia Androgenica
Start: 2022-11-01End: 2023-06-28Updated: 2025-04-16

Related Papers

Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study.
2012-05-24202 citations
Comparing the effect of hydroxyethyl starch 130/0.4 with balanced crystalloid solution on mortality and kidney failure in patients with severe sepsis (6S--Scandinavian Starch for Severe Sepsis/Septic Shock trial): study protocol, design and rationale for a double-blinded, randomised clinical trial.
2011-01-2745 citations